{"id":"pcm-oxy2","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Drowsiness"},{"rate":null,"effect":"Hepatotoxicity (paracetamol-related)"}]},"_chembl":{"chemblId":"CHEMBL2114959","moleculeType":"Small molecule","molecularWeight":"282.38"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Paracetamol reduces pain and fever through inhibition of cyclooxygenase enzymes in the central nervous system. Oxycodone is a semi-synthetic opioid agonist that binds to mu, delta, and kappa opioid receptors in the brain and spinal cord, enhancing pain modulation. The combination allows for synergistic analgesia at lower individual doses, potentially reducing opioid-related adverse effects while maintaining efficacy.","oneSentence":"PCM/Oxy2 is a fixed-dose combination of paracetamol (acetaminophen) and oxycodone that provides analgesia through dual mechanisms: paracetamol's antipyretic and analgesic effects via COX inhibition, and oxycodone's opioid receptor agonism for moderate-to-severe pain relief.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:59:55.641Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate-to-severe acute and chronic pain"}]},"trialDetails":[{"nctId":"NCT02152592","phase":"PHASE4","title":"Controlled-Release Oxycodone Versus Naproxen at Home After Ambulatory Surgery: A Randomized Controlled Trial","status":"COMPLETED","sponsor":"Maastricht University Medical Center","startDate":"2007-10","conditions":"Postoperative Pain After Ambulatory Surgery","enrollment":105}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"PCM/Oxy2","genericName":"PCM/Oxy2","companyName":"Maastricht University Medical Center","companyId":"maastricht-university-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PCM/Oxy2 is a small molecule intervention studied in a clinical trial for postoperative pain after ambulatory surgery. The exact mechanism of PCM/Oxy2 is not specified in the provided information, but it is classified as a small molecule.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}